Roche's sales grow 6% in Q4 to 15.4B Swiss francs

Thursday, 30. January 2020 07:29

Roche's sales increased to 15.4 billion Swiss francs ($15.8 billion) in the fourth quarter of 2019, rising 6% year-on-year as its United States pharmaceuticals division recorded a jump of 11% in sales in the last three months of the year compared to the same period a year ago.

In the full-year 2019, IFRS sales were at 61.5 billion Swiss francs as operating profit came in at 17.5 billion Swiss francs. Net income was reported at 14.1 billion Swiss francs, rising 32%, while diluted earnings per share at the pharmaceutical firm were 15.62 Swiss francs in 2019.

Roche CEO Severin Schwan said: "Roche is very well positioned to grow going forward. For 2020 we expect sales growth in the low- to mid-single digit range in spite of the even greater impact of the competition from biosimilars."

Related Links: Roche Holding
Breaking the News / VP